Drugs / NMS-03305293
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06930755 | May 2026 → May 2027 expected | ovarian cancer | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT06931626 | Aug 2025 → Oct 2026 expected | small cell lung carcinoma | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT04182516 | Nov 2019 → Mar 2023 | — | Nerviano Medical Sciences | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04910022 | Dec 2021 → May 2027 expected | glioblastoma | Nerviano Medical Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-03305293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04910022 ↗ |
| Action | Inhibit | “NMS-03305293 (a PARP inhibitor)” NCT04182516 ↗ |
| Route | Oral | “NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.” NCT04182516 ↗ |
| Target | PARP1 | “NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor” NCT06930755 ↗ |